ReviewFrontiers in molecular biosciences2023
SPARC: a potential target for functional nanomaterials and drugs.
Review in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Triple-helical ligands for collagen-binding proteins improve cartilage extracellular matrix production in nasal chondrocytes.Materials today. Bio · 2026Article
- SPARC modulates macrophage-like phenotype transformation in VSMCs and triggers a vicious cycle.Frontiers in cell and developmental biology · 2026Article
- Investigation of complex miRNA-mRNA interaction networks during JAK inhibitor therapy in rheumatoid arthritis.Frontiers in pharmacology · 2026Article
- Identification of potential predictive biomarkers during JAK-inhibitor therapies in rheumatoid arthritis.Human genomics · 2025Article
- Evaluation of an experimental therapy based on bovine mesenchymal stem cell (MSC) secretome for the treatment of endometritis in dairy cows.Scientific reports · 2025Article
- Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis.International journal of pharmaceutics: X · 2025Review
- SPARC-modified mesenchymal stem cells promote recovery of β-cells and insulin secretion by calcium ion homeostasis.Stem cell research & therapy · 2025Article
- Spatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases.The Journal of pathology · 2025Article
- Differential gene expression drives muscle metabolic and structural differences in Liang Guang small spotted vs. large white pigs.Scientific reports · 2025Article
- Systematic Mendelian Randomization Exploring Druggable Genes for Hemorrhagic Strokes.Molecular neurobiology · 2025Article
- Comparative immunohistochemical evaluation between primary and metastatic lesion in a feline osteosarcoma - A case report.Heliyon · 2025Article
- Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma.iScience · 2024Article
- The in vivo effects of knockdown of long non-coding RNA XIST on fibroid growth and gene expression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- In Vivo Effects of Bay 11-7082 on Fibroid Growth and Gene Expression: A Preclinical Study.Cells · 2024Article
- SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.Frontiers in immunology · 2024Article
- GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.Frontiers in pharmacology · 2024Review
- Obesity and Bone Mineral Density Protection Paradox in Chronic Kidney Disease: Secreted Protein Acidic and Rich in Cysteine as a Piece of the Puzzle?Life (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreted protein acidic and rich in cysteine (SPARC), also termed osteonectin or BM-40, is a matricellular protein which regulates cell adhesion, extracellular matrix production, growth factor activity, and cell cycle. Although SPARC does not perform a structural function, it, however, modulates interactions between cells and the surrounding extracellular matrix due to its anti-proliferative and anti-adhesion properties. The overexpression of SPARC at sites, including injury, regeneration, obesity, cancer, and inflammation, reveals its application as a prospective target and therapeutic indicator in the treatment and assessment of disease. This article comprehensively summarizes the mechanism of SPARC overexpression in inflammation and tumors as well as the latest research progress of functional nanomaterials in the therapy of rheumatoid arthritis and tumors by manipulating SPARC as a new target. This article provides ideas for using functional nanomaterials to treat inflammatory diseases through the SPARC target. The purpose of this article is to provide a reference for ongoing disease research based on SPARC-targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.